Significant Developments: Baidu Group-SW (09888) has proposed the spin-off and separate listing of Kunlunxin on the Main Board of The Stock Exchange of Hong Kong Limited. Dali P Holdings (01921)'s wholly-owned subsidiary, Dali P International Industrial Company, has obtained a Provisional Industrial License issued by MIMR. GUOFUHEE (02582) has completed the delivery of a total of 424 vehicle-mounted high-pressure hydrogen supply systems to its clients. CSPC Pharmaceutical Group (01093) announced that Nintedanib Esilate Powder for Inhalation has received clinical trial approval in China. Fantasia Holdings Group (01777) entered into a restructuring agreement with Splendid Fortune, proposing to sell 409 million shares of Color Life Services for USD 4.5284 million. China Hongqiao Group (01378) stated that Hongtuo Industrial has become a wholly-owned subsidiary of Hongchuang Holdings. Brainact-B (06681)'s subsidiary formally signed a Cognitive Digital Therapy Project Cooperation Agreement with Beijing Jianguo Medical. Longpan Technology (02465) plans to invest in building a lithium iron phosphate production base with an annual capacity of 240,000 tons, with a total investment not exceeding CNY 2 billion. CIFC (00943) intends to acquire a digital solutions company in the beauty industry for HKD 62.5 million, with trading resuming on January 5. Kelun-Biotech Biopharmaceuticals-B (06990) announced that the new drug clinical trial application for ITGB6 ADC SKB105 has been approved by the National Medical Products Administration.